We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Free Testosterone Test Advances Diagnostic Capabilities for Androgen Disorders

By LabMedica International staff writers
Posted on 17 Jan 2025
Print article
Image: The state-of-the-art assay is processed the random-access iSYSTM or i10 TM instruments (Photo courtesy of EUROIMMUN)
Image: The state-of-the-art assay is processed the random-access iSYSTM or i10 TM instruments (Photo courtesy of EUROIMMUN)

A state-of-the-art assay offers direct measurement of free testosterone levels in a single test, significantly improving diagnostic capabilities for conditions such as hypogonadism, impotence, polycystic ovarian syndrome (PCOS), and other androgen-related disorders.

Revvity, Inc. (Waltham, MA, USA) has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s (Lübeck, Germany) automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This groundbreaking test is the first of its kind to receive FDA approval for the direct quantitative measurement of free testosterone levels, marking a major step forward in diagnosing androgen disorders. The advanced assay operates on the company’s random-access iSYSTM or i10TM instruments, offering quick turnaround times and high throughput testing with minimal technician training required, while ensuring exceptional accuracy and reliability.

This FDA-cleared ChLIA assay provides rapid results for the direct quantitative measurement of free testosterone in human serum or plasma. The first result is available in just 48 minutes, with an estimated throughput of nearly 60 tests per hour on EUROIMMUN’s ChLIA platforms. The use of monoclonal antibodies guarantees specificity and consistent performance across test batches.

"Laboratory customers have been asking for a user-friendly FDA-cleared test, on a random-access platform, for direct measurement of free testosterone," said Jonathan Friend, general manager at Revvity’s EUROIMMUN US. "This clearance reinforces our commitment to expanding the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions with assays that serve diverse patient populations across all demographics.”

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
Troponin T QC
Troponin T Quality Control
New
Multi-Channel Pipettor
BioPette Plus
New
C-Terminal Telopeptide ELISA
Urine BETA CrossLaps (CTX-I) ELISA

Print article

Channels

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Pathology

view channel
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Revolutionary AI Tool Transforms Disease Visualization

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.